AAM Urges Biden-Harris Administration To Increase Biosimilar Reimbursement
As IQVIA Study Predicts $69bn-$140bn In US Healthcare Savings Due To Biosimilars
The AAM has urged the US Congress to increase biosimilar reimbursement through higher Medicare Part B add-on payments for biosimilars, based on a recent IQVIA report that has identified a correlation between Medicare payments and biosimilar adoption. The AAM has also urged the CMS to establish a shared savings program.
